We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits

By LabMedica International staff writers
Posted on 12 Mar 2026

Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. More...

A new study shows that different at-home gut health tests—and even repeated tests from the same provider—can produce conflicting bacterial abundance estimates and divergent health categorizations. The findings highlight persistent gaps in standardization.

In work from the National Institute of Standards and Technology, (NIST; Gaithersburg, MD, USA) investigators evaluated commercially available, direct-to-consumer gut microbiome testing kits. These services analyze an individual’s fecal sample to profile microbiome composition and, in many cases, convert those data into health assessments. The team focused on analytical performance across brands and replicate submissions to understand how methodological differences affect reported results.

The study assessed 21 test kits from seven anonymized providers, all analyzing the same combined fecal sample from a single donor. Reported relative abundances of specific taxa varied widely between companies, with the genus Clostridium—encompassing pathogens such as Clostridioides difficile—among the most variable findings. For context, the American Gut Project’s average abundance for Clostridium was just over 2.5%, yet one company reported approximately five times that level, while three others failed to detect the genus in one or more submissions. Within-brand consistency also diverged: three identical samples sent to the same provider yielded conflicting health categorizations, with one labeled “unhealthy” and two labeled “healthy.”

The authors attribute the discrepancies to nonstandardized sampling procedures, sample processing and analysis pipelines, and the distinct metrics individual companies apply to generate health scores. They propose that standardizing sampling protocols and testing methods could improve the accuracy and interpretability of direct-to-consumer microbiome testing. The findings are published in Communications Biology on February 26, 2026.

Related Links
National Institute of Standards and Technology


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Manual Pipetting Aid
Pipette Controllers macro
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image

Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings

Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.